- Lobbying
- Lobbying by Orexigen Therapeutics, Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Paul Kim | Senator Kennedy Director For Health Policy; Congressman |
- - | Waxman counsel; Senator Pryor staff in the U.S. House of Representatives Asst; Sen Charles Schumer, Dir Econ Dev&Approp Congressman Waxman counsel; Legislative Director for Representative Sherrod Brown and Commerce in the U.S. House |
Kevin Brennan | Chief of Staff-Rep. R. DeLauro; Leg. Dir.-Rep. Sherrod Brown Chief of Staff for Representative Rosa DeLauro; |
Rodger Currie | Majority Counsel of the Committee on Energy and Commerce |
Dayle Lewis Cristinzio | Sen Harry Reid, Leg Dir; Rep Steny Hoyer, Sr Leg |
Isa Mirza | n/a |
-- - | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Registration
Issue(s) they said they’d lobby about: Legislative and regulatory matters related to the Food and Drug Administration (FDA) with a focus on the regulation of novel therapeutics for the treatment of obesity..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate